CIS
MRNA icon

Capital International Sarl’s Moderna MRNA Stock Holding History

Capital International Sarl’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,431
Closed -$526K – 280
2024
Q2 		$526K Sell
4,431
-955
-18% -$121K 0.02% 239
2024
Q1 		$574K Buy
5,386
+1,619
+43% +$163K 0.02% 216
2023
Q4 		$375K Sell
3,767
-8,605
-70% -$724K 0.01% 218
2023
Q3 		$1.28M Sell
12,372
-1,432
-10% -$160K 0.06% 191
2023
Q2 		$1.68M Sell
13,804
-2,541
-16% -$339K 0.08% 193
2023
Q1 		$2.51M Buy
16,345
+9,785
+149% +$1.61M 0.13% 162
2022
Q4 		$1.18M Buy
+6,560
New +$1.07M 0.08% 183
2022
Q1 		– Sell
-1,175
Closed -$298K – 269
2021
Q4 		$298K Buy
+1,175
New +$344K 0.01% 249

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital International Sarl's MRNA Position: Q3 2024 in Review

Capital International Sarl sold out of Moderna (MRNA) in Q3 2024, closing a stake of 4,431 shares — an estimated $526K sold.

Capital International Sarl first reported a position in MRNA in Q4 2021 and held it in 8 quarters. The position peaked at $2.51M in Q1 2023. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Capital International Sarl reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Capital International Sarl sold 4,431 Moderna shares in Q3 2024, an estimated $526K.
  • Capital International Sarl first reported a position in Moderna in Q4 2021 and held it in 8 quarters.
  • Capital International Sarl's Moderna position peaked at $2.51M in Q1 2023.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Capital International Sarl's 13F filing for Q3 2024, filed 13 Nov 2024.